PMID- 30896812
OWN - NLM
STAT- MEDLINE
DCOM- 20190703
LR  - 20190703
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 41
IP  - 5
DP  - 2019 May
TI  - Role of natural killer cells for immunotherapy in chronic myeloid leukemia 
      (Review).
PG  - 2625-2635
LID - 10.3892/or.2019.7059 [doi]
AB  - The majority of natural killer (NK) cells serve an important role in eliminating 
      malignant cells. The cytotoxic effects of NK cells were first identified against 
      leukemia cells, and it is now hypothesized that they may have a critical role in 
      leukemia therapy. The cellular functions of NK cells are mediated by their cell 
      surface receptors, which recognize ligands on cancer cells. The role of NK cells 
      is specifically regulated by the activating or inhibitory killer cell 
      immunoglobulin‑like receptors (KIRs) on their surface, which bind to the human 
      leukocyte antigen (HLA) class I ligands present on the target cells. The 
      association between KIR and HLA is derived from the diversity of KIR/HLA gene 
      profiles present in different individuals, and this determines the cytotoxic 
      effect of NK cells on cancer cells. Chronic myeloid leukemia (CML) is a 
      hematological leukemia characterized by the hyper‑proliferation of myeloid cells, 
      with the majority of patients with CML presenting with abnormal immune cells. 
      Tyrosine kinase inhibitors are the present standard therapy for CML, but are 
      associated with numerous adverse side effects. Various studies have proposed CML 
      therapy by immunotherapeutic approaches targeting the immune cells. This review 
      summarizes the contents of NK cells and the association between KIR/HLA and 
      leukemia, especially CML. This is followed by a discussion on the development of 
      NK cell immunotherapy in hematological malignancies and research into strategies 
      to enhance NK cell function for CML treatment.
FAU - Lee, Hye-Rim
AU  - Lee HR
AD  - Department of Biomedical Science, CHA University, CHA General Hospital, Seongnam, 
      Gyeonggi 13488, Republic of Korea.
FAU - Baek, Kwang-Hyun
AU  - Baek KH
AD  - Department of Biomedical Science, CHA University, CHA General Hospital, Seongnam, 
      Gyeonggi 13488, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190313
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Receptors, KIR)
SB  - IM
MH  - Antineoplastic Agents, Immunological/*pharmacology/therapeutic use
MH  - Cell Proliferation/drug effects
MH  - Clinical Trials as Topic
MH  - Histocompatibility Antigens Class I/immunology/metabolism
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Killer Cells, Natural/*drug effects/immunology/metabolism
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug 
      therapy/immunology/pathology
MH  - Receptors, KIR/*antagonists & inhibitors/immunology/metabolism
EDAT- 2019/03/22 06:00
MHDA- 2019/07/04 06:00
CRDT- 2019/03/22 06:00
PHST- 2019/01/08 00:00 [received]
PHST- 2019/02/06 00:00 [accepted]
PHST- 2019/03/22 06:00 [pubmed]
PHST- 2019/07/04 06:00 [medline]
PHST- 2019/03/22 06:00 [entrez]
AID - 10.3892/or.2019.7059 [doi]
PST - ppublish
SO  - Oncol Rep. 2019 May;41(5):2625-2635. doi: 10.3892/or.2019.7059. Epub 2019 Mar 13.